Subscribe

Articles

Use Caution When Placing Catheters in Children with Cancer
By Phoebe Starr
Conference Correspondent
TON - January 2017, Vol 10, No 1
Prospective, observational, and multicenter trials have documented a dramatic increase in venous thromboembolism (VTE) in children with cancer over the past decade. Read More ›
AONN+ Annual Conference Deemed a Success
AONN+ Annual Conference Deemed a Success
By Meg Barbor, MPH
Conference Correspondent, AONN+ News
TON - January 2017, Vol 10, No 1
More than 1000 oncology nurse and patient navigators from across the United States and Canada gathered in Las Vegas for the Academy of Oncology Nurse & Patient Navigators (AONN+) Seventh Annual Navigation & Survivorship Conference. Read More ›
Noteworthy Numbers: Leukemia
Noteworthy Numbers: Leukemia
Noteworthy Numbers
TON - January 2017, Vol 10, No 1
Leukemia is the most common cancer in children and adolescents and represents almost 1 of 3 cancers found in these populations. Read More ›
From the Editor
By Beth Faiman, PhD, APRN-BC, AOCN
From the Editor
TON - January 2017, Vol 10, No 1
The January issue of The Oncology Nurse-APN/PA (TON) is full of important news and updates for oncology nurses Read More ›
Toxicities Associated with Targeted Therapy and Immunotherapy Underreported in Published Studies
Toxicities Associated with Targeted Therapy and Immunotherapy Underreported in Published Studies
By Alice Goodman
Supportive Care
TON - January 2017, Vol 10, No 1
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading. Read More ›
Increased Attention to Cardiovascular Events in DLBCL Warranted
Increased Attention to Cardiovascular Events in DLBCL Warranted
By Phoebe Starr
Conference Correspondent
TON - January 2017, Vol 10, No 1
Patients with diffuse large B-cell lymphoma (DLBCL) are at increased risk for cardiovascular (CV) events, particularly during the first year following diagnosis, and these events shorten their lives, according to a retrospective study. Read More ›
Mounting Evidence for Ki67 as Independent Prognostic Marker
Mounting Evidence for Ki67 as Independent Prognostic Marker
By Alice Goodman
Breast Cancer
TON - January 2017, Vol 10, No 1
Measuring the Ki67 protein, along with traditional risk factors such as tumor size and molecular characteristics, may make it possible to avoid sentinel node biopsy in women aged >50 years with breast cancer. Read More ›
FDA Approves Rucaparib and Companion Diagnostic for Patients with Advanced Ovarian Cancer
FDA Updates, In the News
Web Exclusives
The FDA has granted accelerated approval of rucaparib (Rubraca), a poly ADP-ribose polymerase inhibitor, for the treatment of patients with advanced ovarian cancer whose tumors have deleterious BRCA gene mutation and have been treated with ≥2 chemotherapies. The administration also approved a companion diagnostic to the drug, FoundationFocus CDxBRCA, which is the first next-generation sequencing diagnostic test. Read More ›
Real-World Experience with Taiho Oncology Patient Support for Lonsurf® (trifluridine and tipiracil)
Real-World Experience with Taiho Oncology Patient Support for Lonsurf® (trifluridine and tipiracil)
By Lisa A. Raedler, PhD, RPh, Medical Writer
Patient Assistance Profiler December 2016
As the costs associated with cancer care continue to escalate, all key stakeholders—healthcare providers, private and government payers, and patients—strive to balance high-quality cancer care with cost efficiency. As insurance benefit designs continue to shift the cost burden of treatment, more patients with cancer and their families are both psychologically and financially invested in treatment decisions. Read More ›

Page 187 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.